Results 181 to 190 of about 147,649 (246)

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

m5C‐Modified tRF3b‐CysGCA‐23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4

Advanced Science, EarlyView.
In this study, we identified an NSUN6‐dependent m5C‐modified tsRNA, m5C‐tRF3b CysGCA‐23 (mtRC), that is downregulated in BC and inversely correlated with disease progression. Mechanistically, mtRC suppresses BC malignancy by stabilizing RBM4, attenuating glycolysis, and thereby limiting H3K18 lactylation–mediated activation of IL1RAP and VASH2 ...
Xiaoling Ying, Yapeng Huang, Jian Huang, Qinyu Cai, Danni Zhang, Cong Chen, Yuxi Nie, Baotong Yang, Chuan Li, Wenyu Hu, Chang Xiong, Chengcheng Zhang, Ding Ji, Yaomin Liang, Mei Yang, Wenqi Wu, Weidong Ji   +16 more
wiley   +1 more source

Chromosome 3p Deletion Leads to Extensive Genomic Alterations in Diverse Cancers and Confers Synthetic Lethality in Uveal Melanoma. [PDF]

Cancers (Basel)
Cutler MC, Howland PB, Hejna M, Song JS.
europepmc   +1 more source

POU2F1 Promotes Chemoresistance in Colorectal Cancer Cells via Attenuates the MDR2 Degradation Mediated by PPP1R11 Lactylation

Advanced Science, EarlyView.
Schematic diagram of our study showing that highly expressed POU2F1 in colorectal cancer (CRC) can directly accelerate the cytosolic lactate export to decrease PPP1R11 lactylation at K59, thereby attenuating the E3 ligase enzyme activity and protein stability of PPP1R11, which inhibits the ubiquitination of MDR2 at K413 and K538 but increases the ...
Longzheng Xia, Jinguan Lin, Xianjie Jiang, Linda Oyang, Shiming Tan, Zongyao Ren, Qiu Peng, Qianjin Liao, Yujuan Zhou   +8 more
wiley   +1 more source

Transmembrane protein 9 as a novel biomarker promotes oral squamous cell carcinoma growth via IL1RN and serves as an immune therapeutic target. [PDF]

Transl Cancer Res
Li JH, Dong SD, Zuo YD, Li JC.
europepmc   +1 more source

CircRSU1 Activates the hnRNPA1/HIF‐1α/CD24 Signaling Axis, Promoting Stemness Features of Hepatocellular Carcinoma

Advanced Science, EarlyView.
This study reveals circRSU1 with important oncogenic roles in hepatocellular carcinoma (HCC). CircRSU1, highly abundant in HCC, interacts with and stabilizes hnRNPA1 from ubiquitination and degradation. This stabilization facilitates hnRNPA1 binding to the internal ribosome entry site of HIF1A to increase HIF‐1α protein translation.
Shuting Xue, Danduo Wei, Yongzhi Zhao, Jinchang Pan, Hanyuan Zhang, Niya Liu, Jianjuan Zhang, Jiaxin Liu, Jianping Jin, Mu Xiao, Xinhua Feng, Aifu Lin, Lei Zhao, Stephanie Roessler, Junfang Ji   +14 more
wiley   +1 more source

SeOMLR: one-step multi-view latent representation with self-weighted ensemble learning for multi-omics cancer subtyping. [PDF]

Bioinformatics
Song W, Sun Y, Ou-Yang L.
europepmc   +1 more source

SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis

Advanced Science, EarlyView.
This study highlights the capacity for tumor suppressor SATB2 to recruit HDAC3 and catalyze histone H3K9 delactylation, thereby repress transcription of the oncogene LCN2. This novel epigenetic‐metabolic axis inhibits the growth and metastasis of non‐small cell lung cancer, delineating a new mechanistic pathway with potential therapeutic relevance ...
Ting Wen, Lihua Yang, Shuang Cai, Yunxia Liu, Jianan Fan, Peng Wu, Beibei Gao, Xiaoge Xie, Hong Sun, Sida Qin, Qiao Yi Chen   +10 more
wiley   +1 more source

Short-term hormonal modulation with mifepristone does not induce oncogenic changes in the endometrium of BRCA1/2 pathogenic variant carriers. [PDF]

Commun Med (Lond)
Widschwendter M, Herzog C, Rasul MF, Boggavarapu NR, Redl E, Utjés D, Flöter Rådestad A, Gemzell-Danielsson K, Alkasalias T.   +8 more
europepmc   +1 more source